SCHEMBL18155048

SCHEMBL18155048

Cc1[nH]c2ncccc2c1-c1c[nH]c(=O)c(-c2nc3cc(N4CCNCC4)ccc3[nH]2)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TGFB2 P61812 1/20 0.51
FGFR1 P11362 7/20 0.39
FLT1 P17948 5/20 0.39
PIM1 P11309 5/20 0.38
PIM3 Q86V86 4/20 0.38
PIM2 Q9P1W9 2/20 0.37
MAP4K1 Q92918 2/20 0.37
PDGFRB P09619 4/20 0.37
KDR P35968 4/20 0.37
TGFBR1 P36897 1/20 0.36
ACVR1 Q04771 1/20 0.36
ALK Q9UM73 1/20 0.36
CCND1 P24385 1/20 0.34
CDK6 Q00534 1/20 0.34
CDC7 O00311 1/20 0.34
CDK9 P50750 1/20 0.34
PARP1 P09874 1/20 0.34
HTR1A P08908 1/20 0.33
HTR7 P34969 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18155111 0.92 FGFR1 (0.47) TGFB2FGFR1FLT1MAP4K1PDGFRB
SCHEMBL18155095 0.84 TGFB2 (0.51) TGFB2FGFR1PIM1PIM3PIM2
SCHEMBL20048367 0.81 TGFB2 (0.55) TGFB2FGFR1PIM1PIM3PDGFRB
SCHEMBL18155078 0.80 TGFB2 (0.52) TGFB2PIM1PIM3PIM2CDC7
SCHEMBL18163943 0.80 TGFB2 (0.57) TGFB2FGFR1FLT1PIM1PIM3
SCHEMBL18155028 0.77 TGFB2 (0.49) TGFB2PIM1PIM3PIM2
SCHEMBL18164050 0.76 TGFB2 (0.58) TGFB2FGFR1FLT1PIM1PIM3
SCHEMBL18155106 0.75 TGFB2 (0.52) TGFB2FGFR1FLT1PIM1PIM3
SCHEMBL18155029 0.75 TGFB2 (0.87) TGFB2FGFR1PIM1PIM3PIM2
SCHEMBL18155060 0.74 TGFB2 (0.64) TGFB2FGFR1PIM1PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3283475-B1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2019-10-16 EP claimed
EP-3283475-A1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES Merck Patent GmbH (DE) 2018-02-21 EP claimed
WO-2016165808-A1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2016-10-20 WO claimed
EP-3283475-B1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2019-10-16 EP disclosed
US-10179777-B2 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives MERCK PATENT GMBH (DE) 2019-01-15 US disclosed
US-20180099947-A1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2018-04-12 US disclosed
EP-3283475-A1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES Merck Patent GmbH (DE) 2018-02-21 EP disclosed
WO-2016165808-A1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10179777-B2 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives ALK, ABL2, ACVR1 TGFB2 267/4885FGFR1 26/4885FLT1 31/4885
US-20180099947-A1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES ALK, ABL2, ACVR1 TGFB2 267/4885FGFR1 26/4885FLT1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.